(S)-N1-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-((TETRAHYDROFURAN-3-YL)OXY)QUINAZOLIN-6-YL)-N2,N2-DIMETHYLOXALAMIDE

N1,N2-Bis(4-((3-chloro-4-fluorophenyl)amino)-7-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)oxalamide

Pharmaceutical intermediate for Afatinib impurities

Afatinib Impurity AFT-8

Active pharmaceutical ingredient impurity reference

(R)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((R)-tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)-3-hydroxybutanamide

Pharmaceutical intermediate for afatinib impurities

N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-3,4-bis(dimethylamino)butanamide

Pharmaceutical reference impurity standard

(S)-4-Methyloxazolidine-2,5-dione

pharmaceutical intermediate

1-(4-chlorophenyl)-3-oxoisoindoline

Pharmaceutical intermediate synthesis

4-(4-chlorophenyl)-1H-2,3-benzoxazin-1-one

Pharmaceutical intermediate

3-(trifluoromethyl)pyridin-2-ol

pharmaceutical intermediate